2012 | Aarkstore.com || Multiple Sclerosis – Pipeline Review, H2 2012 by aarks222

VIEWS: 6 PAGES: 4

									Aarkstore.com announces, The Latest market research report is available in
its vast collection:

Multiple Sclerosis – Pipeline Review, H2 2012




You can also request for sample page of above mention reports on
sample@aarkstore.com




Summary

Global Markets Direct’s, Multiple Sclerosis - Pipeline Review, Global Markets
Direct’s, Multiple Sclerosis - Pipeline Review, H2 2012, provides an overview of the
indication’s therapeutic pipeline. This report provides information on the
therapeutic development for Multiple Sclerosis, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Multiple Sclerosis. Multiple Sclerosis -
Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct’s proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets Direct’s
team.

Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
- A review of the Multiple Sclerosis products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under
development for Multiple Sclerosis.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.

Table of contents:

List of Tables 6
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Multiple Sclerosis Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Multiple Sclerosis 13
Multiple Sclerosis Therapeutics under Development by Companies 15
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes 27
Late Stage Products 31
Comparative Analysis 31
Mid Clinical Stage Products 32
Comparative Analysis 32
Early Clinical Stage Products 33
Comparative Analysis 33
Discovery and Pre-Clinical Stage Products 34
Comparative Analysis 34
Multiple Sclerosis Therapeutics – Products under Development by Companies 35
Multiple Sclerosis Therapeutics – Products under Investigation by
Universities/Institutes 40
Companies Involved in Multiple Sclerosis Therapeutics Development 42
Alcon, Inc. 42
Genzyme Corporation 43
Baxter International Inc. 44
F. Hoffmann-La Roche Ltd. 45
Abbott Laboratories 46
Biogen Idec Inc. 47
Amgen Inc. 48
Eli Lilly and Company 49
Athersys, Inc. 50



List of Figures

List of Tables are also include.




For more related Reports Plz follow The link:



Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1



 Liver Cancer – Pipeline Review, H2 2012

 Non-Small Cell Lung Cancer – Pipeline Review, H2 2012

 Asthma – Pipeline Review, H2 2012

 Multiple Sclerosis – Pipeline Review, H2 2012

 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012

 Diabetes – Pipeline Review, H2 2012

 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012

 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,
H2 2012

 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012

 Malaria – Pipeline Review, H2 2012

 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,
H2 2012

 Dermatitis – Pipeline Review, H2 2012




Search More Reports Related to This Category :

Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1




For More details Plz do contact :

Aarkstore Enterprise

Lavanya

Phone:08149852585

Email: enquiry@aarkstore.com

								
To top